Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma.

OBJECTIVE: To evaluate the real-world efficacy and safety of golidocitinib in patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL). METHODS: Clinical data of 3 patients with R/R PTCL treated with golidocitinib at our center between May 2024 and November 2025 were retrospectively analyzed. Baseline features, treatment regimens, responses, and adverse events (AEs) were collected and assessed. RESULTS: Pathological subtypes included PTCL-not otherwise specified (PTCL-NOS, n=2) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, n=1). Following golidocitinib-based therapy, 2 patients achieved complete response (CR) and 1 partial response (PR), yielding an objective response rate (ORR) of 100%. Median follow-up was 6.2 months (range: 4.2-9.1 months); median progression-free survival (PFS) was not reached. Treatment-related AEs were predominantly hematological, mostly grade 1-2 and manageable. No treatment-related deaths occurred. CONCLUSION: Golidocitinib exhibits promising efficacy and a tolerable safety profile in R/R PTCL, including rare subtypes, supporting its role as a valuable therapeutic option. Larger cohorts are needed for further validation.